And here's the link and article:Mesoblast (MSB) $7.9; Neuren...

And here's the link and article:

Mesoblast (MSB) $7.9; Neuren (NEU) 3c

WITH market caps of $2.2bn and $34m respectively, these biotechs are at perverse ends of the valuation spectrum. Both are at pivotal stages in their development and - arguably - are worth more.

Stem-cell play Mesoblast is no stranger to us, having last year inked a $US1.7bn deal with US pharma giant Cephalon (now Teva) to further its advanced trials for congestive heart failure and bone- marrow disorders.

Mesoblast shares have doubled since then, but last week they fell from $9.40 to $7.90, prompting a "please explain" from the bourse. This was management's cue to highlight the progress of its adult stem-cell product Revascor, which on interim trial results has "significantly reduced" the incidence of heart attacks. If this one stacks up, it will be bigger than Texas.

But just to be even handed, we duly note Macquarie Equities yesterday plonked the stock on its "undeperform" list, with a valuation of only $5.80.

Neuren, meanwhile, has had a good month - its shares have almost doubled - but is still in the dog house after an earlier trial failed in late 2008.

http://www.theaustralian.com.au/business/wealth/listed-wealth-managers/story-e6frgac6-1226186142403